Merck, known as MSD outside of the United States and Canada, has entered into a definitive agreement under which it will acquire Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company.   Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of EyeBio for up to $3 billion, including an upfront payment of $1.3 billion in cash and a further potential $1.7 billion in developmental, regulatory and commercial milestone p...